Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA

Documenti analoghi

• Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial
  di: Tillman, Holly, et al.
  Pubblicazione: (2019)
• Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: rationale and design
  di: Johnston, S. Claiborne, et al.
  Pubblicazione: (2013)
• Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials
  di: Pan, Yuesong, et al.
  Pubblicazione: (2019)
• Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial
  di: de Havenon, Adam, et al.
  Pubblicazione: (2021)
• Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis
  di: Farrant, Mary, et al.
  Pubblicazione: (2019)